KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 64 filers reported holding KALA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $23,253,000 | -0.6% | 3,450,000 | 0.0% | 0.34% | -3.9% |
| Q4 2020 | $23,391,000 | -9.6% | 3,450,000 | 0.0% | 0.36% | -29.2% |
| Q3 2020 | $25,875,000 | -28.6% | 3,450,000 | 0.0% | 0.51% | -35.7% |
| Q2 2020 | $36,259,000 | +39.7% | 3,450,000 | +16.8% | 0.79% | -6.3% |
| Q1 2020 | $25,956,000 | +1794.6% | 2,952,899 | +4821.5% | 0.84% | +978.2% |
| Q3 2017 | $1,370,000 | – | 60,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,430,021 | $9,638,000 | 6.26% |
| RA Capital Management | 10,874,613 | $73,295,000 | 1.10% |
| Mesirow Financial Investment Management, Inc. | 41,961 | $283,000 | 0.77% |
| Samsara BioCapital, LLC | 601,162 | $4,052,000 | 0.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $689,000 | 0.38% |
| Eventide Asset Management | 3,450,000 | $23,253,000 | 0.34% |
| Orbimed Advisors | 5,465,030 | $36,834,000 | 0.34% |
| Parkman Healthcare Partners LLC | 148,433 | $1,000,000 | 0.23% |
| Vivo Capital, LLC | 786,883 | $5,304,000 | 0.19% |
| Knights of Columbus Asset Advisors LLC | 199,954 | $1,348,000 | 0.13% |